N/A N=200 Therapy™ Cool Flex™ Irrigated Ablation System for Typical Atrial Flutter
Typical Atrial Flutter
Primary: Primary Safety: Incidence of Composite, Serious Adverse Events Within 7 Days Post-Procedure — 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=115 AcQBlate Force Sensing Ablation System US IDE for Atrial Flutter (AcQForce Flutter)
Typical Atrial Flutter
Primary: Subjects Free From Procedure/Device Related Serious Adverse Events (SAEs) — 115 Participants
Phase 4 N=291 Catheter Evaluation for Endocardial Ablation in Patients With Typical Atrial Flutter
Atrial Flutter
Primary: Percentage of Subjects With Complete Bidirectional Conduction Block. — 93.3 percentage of participants — p=.05
Phase 3 N=150 Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System
Typical Atrial Flutter
Primary: Primary Safety:Incidence of Composite, Serious Adverse Events Within 7 Days Post Procedure — 3 participants
Phase 4 N=463 Isthmus Ablation With Gold Electrode for Treatment of Atrial Flutter (AURUM 8)
Atrial Flutter
Primary: Duration of Energy Application — 10.2; 10.9 minute — p=0.25
Phase 3 N=188 Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)
Typical Atrial Flutter
Primary: Primary Safety- Incidence of Intra Procedural Serious Cardiac Adverse Events Occuring Within 7 Days of Post-procedure, Regardless of Whether a Determination Can be Made…
N/A N=5 Multipolar Mapping and Atrial Arrhythmias
Atrial Fibrillation or Atrial Flutter
Primary: Atrial Fibrillation Dominant Frequency
N/A N=80 The FARAPULSE PersAFOne III Trial for the Treatment of Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint: Composite Safety Endpoint (CSE) Defined as the Incidence of the Following Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are…
N/A N=302 Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter
Atrial Flutter
Primary: Procedure-related Complication-free Rate — 92.7; 98.2 percentage of subjects
N/A N=102 Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus
Atrial Fibrillation
Primary: Time to Imaging — 28.1; 7.1 hours
N/A N=24 Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants
N/A N=28 Feasibility Study of the FARAPULSE Endocardial Multi Ablation System in the Treatment of Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Safety at 30 Days — 1 Participants
Phase 4 N=92 Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate
Atrial Fibrillation With Rapid Ventricular Response · Hypotension Drug-Induced
Primary: Mean Difference in Systolic Blood Pressure — -11.7500; -19.5385 mmHg
Phase 3 N=210 Tailored Treatment of Permanent Atrial Fibrillation
Atrial Fibrillation
Primary: Chronic Effectiveness — 56; 26 percentage of participants with success — p=<0.0001
N/A N=41 Curing Atrial Fibrillation in Heart Failure
Chronic Heart Failure · Atrial Fibrillation
Primary: Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)% — 2.8; 4.5 percentage of blood ejected in one beat
Phase 4 N=54 Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter
Heart Rate and Rhythm Disorders
Primary: Percent of Patients Reaching Target HR<100bpm Within 30 Minutes — 46.4; 95.8 percentage of participants — p=.0001
N/A N=362 Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System
Atrial Fibrillation
Primary: Pivotal Main Phase Modified Intent-To-Treat (mITT) Analysis Set: Number of Participants With Primary Adverse Events (PAEs) — 8 Participants
N/A N=31 Characterising the Stable and Dynamic Left Atrial Substrate in Atrial Fibrillation
Atrial Fibrillation
Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV
N/A N=35 Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial
Atrial Fibrillation · Arrhythmias, Cardiac
Primary: Recurrence Rate of Atrial Arrhythmias — 8; 14; 7; 1 participants — p=0.047
Phase 3 N=127 First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)
Atrial Fibrillation
Primary: Number of Participants With Recurrence of Atrial Tachyarrhythmia — 36; 44 Participants — p=0.0016
N/A N=15 A Single Arm Pilot Study of Pulsed Field Ablation in the Treatment of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Occurence of Device-or Procedure-related Early and Late-onset of Serious Adverse Events — 0 Participants
N/A N=3,160 Exclusion of Intra-atrial Thrombus Before Catheter Ablation
Atrial Fibrillation · Thrombi
Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants
Phase 3 N=523 Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
Postoperative Atrial Fibrillation
Primary: Total Number of Days in Hospital — 5.1; 5.0 days — p=0.76
N/A N=607 The FARAPULSE ADVENT PIVOTAL Trial PFA System vs SOC Ablation for Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Composite Safety Endpoint;Proportion of MITT Subjects With One or More of the Specified Device or Procedure Related SAEs — 6; 4 Participants
N/A N=26 Dual Epicardial Endocardial Persistent Atrial Fibrillation(AF) Study (Staged DEEP)
Atrial Fibrillation
Primary: Number of Patients With Pre-specified Safety Endpoints Occurring in the First 30 Days Post-index Procedure or Hospital Discharge, Whichever is Longer. — 3 Participants
N/A N=83 Effectiveness of Ripple Mapping in Atrial Tachycardia Ablation
Atrial Tachycardia
Primary: A Composite of the Total Number of Participants With Either Tachycardia Change or Tachycardia Termination With First Ablation Set. — 38; 29 Participants
Phase 4 N=83 Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation
Atrial Fibrillation
Primary: Proportion of Subjects Who Were Free From Atrial Arrhythmia at One Year. — 10; 18; 29; 20 participants — p=0.048
Phase 2 N=171 Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305
Atrial Fibrillation
Primary: Dose-response Relationship for QTcF Interval of AZD1305 — 461; 486; 490; 482 ms
Phase 3 N=55 AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation
Atrial Fibrillation
Primary: Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months. — 74 percentage of subjects
Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants